Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease

Fertility and Sterility

Volumn 91, Issue 6, 2009, Pages 2545-2550

  Oktem, Mesut ^a   Ozcimen, Emel Ebru ^a   Uckuyu, Ayla ^a   Esinler, Ibrahim ^b   Pamuk, Baris ^a   Bayraktar, Nilufer ^a   Kulaksizoglu, Sevsen ^a   Zeyneloglu, Hulusi B ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

C reactive protein; coronary artery disease; homocysteine; Polycystic ovary syndrome; sCD40L

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; ESTRADIOL; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; INSULIN BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; TURKEY (REPUBLIC);

ADULT; AMENORRHEA; BIOLOGICAL MARKERS; CD40 LIGAND; CORONARY DISEASE; FEMALE; HOMOCYSTEINE; HUMANS; INSULIN; OLIGOMENORRHEA; POLYCYSTIC OVARY SYNDROME; REFERENCE VALUES; WAIST-HIP RATIO; YOUNG ADULT;

EID: 67349219374     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.03.039     Document Type: Article

References (33)

1. Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., and Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004) 2745-2749
2. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19 (2004) 41-47
3. Yarali H., Yildirir A., Aybar F., Kabakci G., Bukulmez O., Akgul E., et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 76 (2001) 511-516
4. Legro R.S., Kunselman A.R., Dodson W.C., and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999) 165-169
5. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
6. Legro R.S., Kunselman A.R., and Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111 (2001) 607-613
7. Tiras M.B., Yalcin R., Noyan V., Maral I., Yildirim M., Dortlemez O., et al. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum Reprod 14 (1999) 1949-1952
8. Kelly C.J., Speirs A., Gould G.W., Petrie J.R., Lyall H., and Connell J.M. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 742-746
9. Orio Jr. F., Palomba S., Spinelli L., Cascella T., Tauchmanova L., Zullo F., et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89 (2004) 3696-3701
10. Vural B., Caliskan E., Turkoz E., Kilic T., and Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 20 (2005) 2409-2413
11. Christian R.C., Dumesic D.A., Behrenbeck T., Oberg A.L., Sheedy II P.F., and Fitzpatrick L.A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2562-2568
12. Schonbeck U., and Libby P. CD40 signaling and plaque instability. Circ Res 89 (2001) 1092-1103
13. Lutgens E., and Daemen M.J. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 12 (2002) 27-32
14. Ahn E.R., Lander G., Jy W., Bidot C.J., Jimenez J.J., Horstman L.L., et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114 (2004) 143-148
15. Garlichs C.D., John S., Schmeisser A., Eskafi S., Stumpf C., Karl M., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395-2400
16. Varo N., Vicent D., Libby P., Nuzzo R., Calle-Pascual A.L., Bernal M.R., et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 107 (2003) 2664-2669
17. Schonbeck U., Varo N., Libby P., Buring J., and Ridker P.M. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266-2268
18. Miller K.K., Rosner W., Lee H., Hier J., Sesmilo G., Schoenfeld D., et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab 89 (2004) 525-533
19. Novo S., Basili S., Tantillo R., Falco A., Davi V., Novo G., et al. Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke 36 (2005) 673-675
20. Apridonidze T., Essah P.A., Iuorno M.J., and Nestler J.E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 1929-1935
21. Sanguigni V., Pignatelli P., Lenti L., Ferro D., Bellia A., Carnevale R., et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111 (2005) 412-419
22. Semb A.G., van Wissen S., Ueland T., Smilde T., Waehre T., Tripp M.D., et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 41 (2003) 275-279
23. Gokulakrishnan K., Deepa R., Mohan V., and Gross M.D. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome-the Chennai Urban Rural Epidemiology Study. Metabolism 55 (2006) 237-242
24. Boulman N., Levy Y., Leiba R., Shachar S., Linn R., Zinder O., et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 89 (2004) 2160-2165
25. Lin R., Liu J., Gan W., and Yang G. C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Biol Pharm Bull 27 (2004) 1537-1543
26. Lin R., Liu J., Peng N., Yang G., Gan W., and Wang W. Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull 28 (2005) 1630-1634
27. Thurberg B.L., and Collins T. The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol 9 (1998) 387-396
28. Guldiken S., Demir M., Arikan E., Turgut B., Azcan S., Gerenli M., et al. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res 119 (2007) 79-84
29. Azar R.R., Badaoui G., Sarkis A., Kassab R., Salame E., Klayme S., et al. Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease. Am J Cardiol 95 (2005) 236-240
30. Schachter M., Raziel A., Friedler S., Strassburger D., Bern O., and Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Hum Reprod 18 (2003) 721-727
31. Yilmaz M., Bukan N., Ayvaz G., Karakoc A., Toruner F., Cakir N., et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 20 (2005) 3333-3340
32. Lee A.B., Godfrey T., Rowley K.G., Karschimkus C.S., Dragicevic G., Romas E., et al. Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Intern Med J 36 (2006) 237-243
33. Weber M., Rabenau B., Stanisch M., Nef H.M., Mollmann H., Elsasser A., et al. Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes. Thromb Res 120 (2007) 811-814